Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PPAR Alpha (LY518674): A Phase 2 Study of the Combinatorial Effect of LY518674 and Atorvastatin in Subjects With Hypercholesterolemia

NCT00133380 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT00133380
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00133380 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PPAR Alpha (LY518674): A Phase 2 Study of the Combinatorial Effect of LY518674 and Atorvastatin in Subjects With Hypercholesterolemia
Lead sponsor
Eli Lilly and Company
Phase
Phase 2
Overall status
Completed
Start date
July 31, 2005
Completion date
September 30, 2006
Enrollment
300
Sites
28

Conditions

As the registry lists them; a condition with its own page is linked.

hypercholesterolemia